Immunosuppressive and biologic therapy: The utility of interferon-gamma release assays (IGRAs) for patients

In this webinar, join Dr. Shereen Mahmood, Rheumatologist at Montefiore Medical Center, as she explores interferon-gamma release assays, and how they serve as a primary screening method for patients with tuberculosis (TB) and taking immunosuppressive or biologic therapies to combat the disease. Mahmood will also provide a review of active versus latent TB infections and reveal more about the role of TNF-alpha antagonists therapy against TB.

Key learning objectives

• Understand the difference between active versus latent TB infections
• Learn more about the role of TNF-alpha antagonists therapy for those at an increased risk of TB infection
• Hear a review of IGRA/QFT-Plus results for patients on immunosuppressive therapy
• Explore the TB screening algorithm, as endorsed by the American College of Rheumatology

Who should attend?

Those working within:

• Rheumatology
• Dermatology
• Gastroenterology
• Infectious disease
• Pulmonary and primary care or family medicine
• Providers who start and monitor patients on immunosuppressive medications and biologic therapy
• Research scientists

Certificate of attendance

All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.